Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fresenius Medical Care Ag ADR (FMS)

Fresenius Medical Care Ag ADR (FMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,643,798
  • Shares Outstanding, K 586,830
  • Annual Sales, $ 20,923 M
  • Annual Income, $ 582,080 K
  • EBIT $ 1,662 M
  • EBITDA $ 3,548 M
  • 60-Month Beta 0.89
  • Price/Sales 0.60
  • Price/Cash Flow 4.80
  • Price/Book 0.84

Options Overview Details

View History
  • Implied Volatility 105.23% (-54.95%)
  • Historical Volatility 28.55%
  • IV Percentile 90%
  • IV Rank 58.60%
  • IV High 160.17% on 12/02/25
  • IV Low 27.44% on 08/18/25
  • Expected Move (DTE 13) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 2,946
  • Open Int (30-Day) 2,956
  • Expected Range 23.25 to 23.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.74
  • Number of Estimates 3
  • High Estimate 0.78
  • Low Estimate 0.70
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +54.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.51 +3.29%
on 11/20/25
24.63 -5.60%
on 11/06/25
-1.00 (-4.12%)
since 11/05/25
3-Month
22.51 +3.29%
on 11/20/25
27.64 -15.88%
on 10/09/25
-1.52 (-6.14%)
since 09/05/25
52-Week
22.05 +5.44%
on 01/13/25
30.46 -23.67%
on 05/21/25
-0.93 (-3.85%)
since 12/05/24

Most Recent Stories

More News
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

BAD HOMBURG, Germany , Nov. 4, 2025 /PRNewswire/ -- "In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income 2 growth increased as...

FMS : 23.25 (-0.51%)
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025

BAD HOMBURG, Germany , Oct. 30, 2025 /PRNewswire/ -- Fresenius Medical Care AG (FME), the world's leading provider of products and services for people with kidney diseases, will present new research...

FMS : 23.25 (-0.51%)
Fresenius Medical Care (FMS) was downgraded to a Sell Rating at Bank of America Securities

Bank of America Securities analyst Marianne Bulot downgraded Fresenius Medical Care to a Sell today and set a price target of $22.00. The company’s shares opened today at $26.70.Elevate Your Investing...

FMS : 23.25 (-0.51%)
Bank of America Securities downgrades Fresenius Medical Care AG & Co. KGaA (0H9X) to a Sell

Fresenius Medical Care AG & Co. KGaA received a Sell rating and a €38.00 price target from Bank of America Securities analyst Anna Ractliffe today. The company’s shares closed yesterday at €47.55.Elevate...

FMS : 23.25 (-0.51%)
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement

BAD HOMBURG, Germany , Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with...

FMS : 23.25 (-0.51%)
Is DaVita Stock Underperforming the Nasdaq?

As DaVita has considerably underperformed the Nasdaq recently, analysts remain cautious about the stock’s prospects.

$NASX : 23,578.13 (+0.31%)
FMS : 23.25 (-0.51%)
DVA : 117.39 (+0.09%)
Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment

BAD HOMBURG, Germany , Sept. 18, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today...

FMS : 23.25 (-0.51%)
The $1.4 Trillion Cardiovascular Disease Crisis: Why Revolutionary Blood Purification Could Transform Treatment Access

Cardiovascular disease remains the world's leading cause of death, claiming more than 17.9 million lives annually according to the World Health Organization . Despite decades of medical advances, existing...

RMTI : 0.9869 (-3.25%)
FMS : 23.25 (-0.51%)
PFE : 26.03 (+1.28%)
DVA : 117.39 (+0.09%)
SIGY : 1.8200 (-9.00%)
Encompass Health Q2 Earnings Beat Estimates, Stock Up 7.4%

Shares of Encompass Health Corp EHC have risen 7.4% since it reported second-quarter 2025 results on Aug. 4. The quarterly results were aided by strong net patient revenue per discharge and capacity expansion...

EHC : 112.50 (-0.46%)
WST : 280.23 (-0.55%)
FMS : 23.25 (-0.51%)
THC : 210.00 (-1.01%)
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced...

FMS : 23.25 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Fresenius Medical Care AG & Co. KGaA is one of the largest integrated providers of products and services for individuals undergoing dialysis. Fresenius Medical provides products and services across the entire dialysis value chain throughout the World. Fresenius Medical manufactures a variety of durable...

See More

Key Turning Points

3rd Resistance Point 23.74
2nd Resistance Point 23.64
1st Resistance Point 23.44
Last Price 23.25
1st Support Level 23.14
2nd Support Level 23.04
3rd Support Level 22.84

See More

52-Week High 30.46
Fibonacci 61.8% 27.25
Fibonacci 50% 26.25
Fibonacci 38.2% 25.26
Last Price 23.25
52-Week Low 22.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar